Abstract Docosahexaenoic acid (DHA), a PUFA of the n-3 family, inhibited the growth of FM3A mouse mammary cancer cells by arresting their progression from the late-G 1 to the S phase of the cell cycle. DHA upregulated p27
.
MAP kinase (MAPK) inhibition by DHA did not increase p27
Kip1 mRNA levels. Rather, this fatty acid stabilized p27
Kip1 contents and inhibited MAPK-dependent proteasomal degradation of this protein. DHA also diminished cyclin E phosphorylation, cyclin-dependent kinase-2 (CDK2) activity, and phosphorylation of retinoblastoma protein in these cells. Our study shows that DHA arrests cell growth by modulating the phosphorylation of cell cycle-related proteins.-Khan, N. A., K. Nishimura, V. Aires, T. Yamashita, D. Oaxaca-Castillo, K. Kashiwagi, and K. Igarashi. Docosahexaenoic acid inhibits cancer cell growth via p27 During the recent past, there has been an upsurge of information on the role of PUFAs in health and disease (1) (2) (3) (4) . As far as cancer growth is concerned, the epidemiological studies have demonstrated that n-6 PUFAs exert stimulatory effects (5) , whereas the n-3 PUFAs have suppressive activity on cancer cell proliferation (6) (7) (8) . These observations are supported by other studies, which have demonstrated enhancing effects of high-fat diets (6, 9) and inhibitory effects of dietary n-3 PUFAs (10) on experimental carcinogenesis. In vitro studies have also shown that n-6 PUFAs stimulate the growth of human breast (11, 12) and prostate (13) cancer cell lines, whereas docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) inhibit their growth (14, 15) .
The G 1 phase of the cell cycle, regulated by stimulatory and inhibitory growth factors, is the most important step with respect to the control of cell proliferation (16, 17) . In normal growth-stimulated cells, the levels of cyclin D and cyclin E are increased, respectively, in the mid-G 1 and late-G 1 phases of the cell cycle (16, 17) . Cyclin D and cyclin E associate, respectively, with cyclin-dependent kinase 4/6 (CDK4/6) and CDK2 to form active kinase complexes (16) . The activity of CDKs is regulated by their specific dephosphorylation and phosphorylation, and by interactions with distinct CDK inhibitors like Cip and Kip family proteins, which inhibit, respectively, cyclin D/CDK4/6 and cyclin E/CDK2 (18, 19) . The activities of cyclin D/ CDK4/6 and cyclin E/CDK2 complexes reach their maximum, respectively, in mid-to-late-G 1 and late-G 1 -to-S-phase transition (20) . Cyclin D/CDK4/6 and cyclin E/CDK2 complexes phosphorylate retinoblastoma protein (pRb) (21, 22) . In quiescent cells, pRb is in a hypophosphorylated active form, but after growth stimulation, it starts to become phosphorylated in the mid-G 1 phase, and maximal phosphorylation occurs at the late-G 1 -to-S-phase junction (22) . The increased phosphorylation of pRb leads to its functional inactivation, resulting in the release of S-phase-specific transcription factors that are bound to and sequestered by unphosphorylated pRb during the G 1 phase of the cell cycle (23) .
Nevertheless, there is a lack of information on the mechanism of action of these fatty acids in the modulation of cancer cell proliferation. Therefore, the present study was designed to shed light on the role of DHA, the terminal molecule of n-3 PUFA metabolism, in the modulation of mouse mammary FM3A cancer cell growth.
MATERIALS AND METHODS

Materials
Essential seiyaku (ES) medium was procured from Nissui Pharmaceutical Co. (Tokyo, Japan). Unless otherwise stated, all other chemicals, including DHA (22:6n-3) and arachidonic acid (AA, 20:4n-6) were purchased from Sigma (St. Louis, MO). Anti-cyclin D1, anti-cyclin E, anti-p27 Kip1 , and CDK2 were purchased from Santa Cruz Biotechnology. FUT-175 was kindly supplied by Torii Pharmaceutical Co. (Tokyo, Japan). Anti-phosphorylated antitotal mitogen-activated protein (MAP) kinase (MAPK) (ERK1/ ERK2) antibodies were obtained from Cell Signaling. Anti-hypoRb and anti-pRb antibodies were procured from Pharmingen.
Plasmids
The dominant negative (S222A) hemagglutinin-1-tagged MAPK extracellularly signal-regulated kinase kinase-1 [MEK-1 (MEK SA )] and constitutively active (S218D/S222D) MEK-1 (MEK DD ) constructs were kindly provided by Alain Eychène (Orsay, France) and Stéphane Manenti (Toulouse, France). They were cloned into the pcDNA 3 expression vector between the HindIII and XbaI restriction sites. After transformation into Echerichia coli DH5a efficiency-competent cells (Invitrogen; Paisely, UK), plasmid constructs were purified by using Plasmid Midi and Maxi kits (Qiagen GmbH, Germany) according to the instructions of the manufacturer.
Cell culture
Mouse mammary FM3A cancer cells were cultured routinely (1 3 10 4 cells/ml) in ES medium supplemented with 50 U/ml streptomycin, 100 U/ml penicillin G, and 2% (v/v) heat-inactivated fetal calf serum (FCS) at 378C in a humidified chamber containing 95% air and 5% CO 2 , as described by Ayusawa, Iwata, and Seno (24) . Cell numbers were determined by hemocytometer. DHA, dissolved in ethanol at a concentration of 0.01% (v/v), was kept under nitrogen in order to minimize its oxidation.
Cell proliferation assays
The cells were serum-starved for 6 h, washed, and further cultured in the aforesaid conditions in the ES medium containing 0.2% FCS with or without DHA at the concentrations stated in the figure legends. Trypan blue was employed to check cell viability and to count cell numbers.
Transient cell transfection
Routinely cultured (1 3 10 4 cells/ml) mouse mammary FM3A cancer cells were washed and then plated at 1 3 10 4 cells/well in 24-well dishes, and transient transfection was performed using Xtreme-GENE Q2 transfection reagent (Roche Applied Science; Paris, France). For cell transfection, 25.7 mg of plasmid DNA was diluted with 750 ml of DNA-dilution reagent, which was further mixed with 750 ml of transfection reagent. The mixed solution was added drop by drop to the cells. Nontransfected cells (control) received all transfection reagents except cDNA. After 36 h, control and transfected cells were used for experiments. The control cells were transfected with pcDNA 3 empty vector.
Cell cycle analysis
The cells were serum-starved for 6 h, washed, and cultured for 12 h in ES medium containing 0.2% FCS with or without DHA. After washing, the cells were fixed in cold 90% ethanol for the cell cycle studies by FACScan flow cytometer (Beckton-Dickinson). The measurement of the cell cycle progression was performed essentially according to the protocol of Ffrench et al. (25) by staining the cell nuclei with propidium iodide (PI). Before the addition of PI, the cells were treated with RNase. After eliminating the cell debris, the different stages of the cell cycle were deduced from the histograms, using the software provided by the manufacturer.
Real-time RT-PCR quantification of p27
Kip1 expression
Total RNA was extracted using Trisol (Invitrogen Life Technologies; Groningen, the Netherlands) according to the manufacturer's instructions. The integrity of the RNA was electrophoretically checked by ethidium bromide staining and by the optical density (OD) absorption ratio OD 260nm /OD 280nm . 1.9. One microgram of total RNA was reverse transcribed with Superscript II RNase H reverse transcriptase using oligo (dT) according to the manufacturer's instructions (Invitrogen Life Technologies). Real-time PCR was carried out on the iCycler iQ real-time detection system (Bio-Rad; Paris, France), and amplification was undertaken using SYBRT Green I. Oligonucleotide primers, used for p27
Kip1 mRNA analysis, were as follows: upstream primer 59-CGGCGGCAAGGTTTGGAGAGG-39; downstream primer, 59-GGAGGAGGCAGGAGGAGGTGG-39. The sequences of the PCR primers for b-actin were as follows: upstream primer, 59-GGCACCACACCTTCTACAATGAGC-39; downstream primer, 59-CGACCAGAGGCATACAGGGACAG-39. The amplification was carried out in a total volume of 25 ml containing 12.5 ml SYBRT Green supermix PCR buffer [50 mM KCl, 20 mM Tris-HCl (pH 8.4), 3 mM MgCl 2 ], 0.2 mM each dNTPs, 0.63 U iTaq DNA polymerase, SYBRT Green, 1.10 nM fluorescein, and 12.5 ml containing 0.3 mM of each primer and diluted cDNA. RT-PCR was performed at an annealing temperature of 628C, 30 cycles. Results were evaluated by iCycler iQ software including standard curves, amplification efficiency, and cycle threshold.
Western blot of cell cycle proteins and MAPK
The cells were serum-starved for 6 h, washed, and cultured in ES medium containing 0.2% FCS with or without DHA (10 mM). The cells were cultured for times as indicated in the figure legends. After washing, the cells were lysed with 50 ml of buffer containing the following: HEPES, 20 mM, pH 7.3; EDTA, 1 mM; EGTA, 1 mM; NaCl, 0.15 mM; Triton X-100, 1%; glycerol, 10%; phenylmethylsulfonyl fluoride, 1 mM; sodium orthovanadate, 2 mM; antiprotease cocktail, 2 ml in 1 ml of buffer (Sigma). After centrifugation (2,500 g 3 1 min), cell lysates were used immediately or stored at 2808C. Protein concentration was determined by the method of Lowry et al. (26) . Denatured proteins (20 mg) were separated by SDS-PAGE (10%) and transferred to polyvinylidine difluoride membranes. Membranes were blocked by incubation with cream-free milk overnight at 48C. Immunodetection was performed by using anti-p27
Kip1 , anti-phosphorylated ERK1/ERK2, anti-total ERK1/ERK2, anti-cyclin D1, anti-cyclin E, and anti-CDK2 (2 mg/ml). After treating the membranes with peroxidase-conjugated secondary antibodies (goat anti-rabbit for anti-p27 Kip1 , goat anti-mouse for ERK1/ERK2, and goat anti-rat DHA modulates growth of FM3A cellsfor all other proteins), peroxidase activity was detected with ECL reagents (Amersham, France).
Assays of CDK2 kinase activity
The cell lysates prepared for Western blot assays were precleared by the incubation with protein A-Sepharose-4B followed by centrifugation (10,000 g 3 15 min). CDK2 kinase assays were performed by the phosphorylation of H1 histone, as per the protocol of Terano et al. (27) . The supernatant was incubated with anti-CDK2 antibody and precipitated with protein A-Sepharose-4B. The H1 histone kinase assays were performed at 308C for 30 min in the following buffer: 100 mg/ml H1 histone, ATP (50 mM), and [
32 P]ATP (5 mCi). Phosphorylated H1 histone was analyzed by SDS-PAGE (10%) and autoradiography.
Detection of state of hypo-or hyperphosphorylation of pRb
The hypophosphorylated pRb (hypo-pRb) was determined by the ratio of hypo-pRb to total pRb by flow cytometry as described by Siddiqui et al. (28) . In brief, the cells were serum-starved for 6 h, washed, and cultured in ES medium containing 0.2% FCS with or without DHA (10 mM) for different times, as mentioned in the figure legends. The cells were washed with PBS for 15 min and then fixed with 1% (v/v) formaldehyde in PBS for 15 min at 48C. Cells were then washed with PBS and suspended in 1 ml of ice-cold 80% (v/v) ethanol and incubated for 2 h at 2208C. The ethanol-fixed cells were washed again and suspended in 1 ml of 0.25% (v/v) Triton X-100 in PBS on ice for 5 min. After centrifugation (800 g 3 5 min), cells were incubated with two antibodies: 0.5 mg/100 ml of FITC-conjugated anti-hypoRb, which recognized the hypophosphorylated form; and PE-conjugated anti-pRb, which recognized total pRb protein. Quantification of the ratio of hypo-pRb to total pRb was performed using a FACScan flow cytometer (Beckton-Dickinson).
Statistical analysis
Results are shown as means 6 SD for quadruplicate assay samples, reproduced independently at least three times. Statistical analysis of data was carried out with Statistica (version 4.1; Statsoft, Paris, France). The significance of the differences between mean values was determined by one-way ANOVA, followed by a least-significant-difference test.
RESULTS
DHA inhibits growth of FM3A mouse mammary cancer cells
To assess the effects of DHA on cell growth, we employed physiological concentrations of this agent. We observed that DHA at 5 mM and 10 mM exerted dosedependent inhibitory effects on the proliferation of FM3A cells (Fig. 1A) . It is noteworthy that AA, an n-6 PUFA, failed to significantly inhibit cell growth at both 5 mM and 10 mM (Fig. 1B) . For further experiments, we employed DHA only at 10 mM, because this is the concentration that exerts cytostatic effects. However, at a concentration of 20 mM, this fatty acid induced cell necrosis (results not shown).
DHA inhibits cell cycle progression
Because the effects of DHA were cytostatic, we were tempted to assess whether this fatty acid exerts its effects on cell cycle progression. We, therefore, conducted cell cycle studies. Figure 2 shows that the number of cells in the S phase of the cell cycle was increased in serum-stimulated cells. On the other hand, DHA treatment of these cells decreased the number of cells in the S phase and increased those in the G0/G 1 phase of the cell cycle.
DHA upregulates p27
Kip1 levels by inhibiting the phosphorylation of MAP kinases
To study the mechanisms responsible for cell cycle arrest, the upstream events known to play a role in the phosphorylation of pRb were investigated. In fact, p27 Kip1 proteolysis leads to the phosphorylation of pRb and the release of E2F-1 transcription factor. Figure 3A shows that quiescent cells abundantly express p27
Kip1 protein, although these cells do not express a detectable quantity of phosphorylated ERK1/ERK2. Stimulation of cell proliferation by serum is associated with p27
Kip1 downregulation and MAPK phosphorylation. Addition of DHA to serumstimulated cells diminished MAPK phosphorylation and upregulated p27
Kip1 levels in FM3A cells (Fig. 3A) . Figure 3B shows that U0126, a MAPK inhibitor, also inhibited serum-stimulated downregulation of p27
Kip1 by inhibiting MAPK phosphorylation. Phorbol-12-myristate-13-acetate (PMA) is known to activate MAPK via activation of protein kinase C (29) . Interestingly, DHA further inhibited the PMA-induced downregulation of p27
Kip1 by inhibiting PMA-stimulated ERK1/ERK2 phosphorylation in these cells (Fig. 3B) Kip1 levels. In these experiments, DHA was used at 10 mM, a concentration that is only sufficient to diminish endogenous MAPK phosphorylation.
DHA does not increase p27
Kip1 mRNA levels
Because DHA was found to upregulate p27 Kip1 levels in FM3A cells, we were tempted to assess whether this fatty acid increases its mRNA levels. Hence, we employed quantitative real-time RT-PCR. Serum stimulation of cell proliferation increased p27
Kip1 mRNA levels for 9 h, after which levels remained unchanged until 12 h (results not shown). Serum-stimulated cells containing DHA and U0126 did not possess lower quantities of p27
Kip1 mRNA than the serum-stimulated-only cells (Fig. 3C ). These observations indicate that inhibition of MAPK phosphorylation does not increase p27
Kip1 mRNA quantities; rather, this phenomenon may trigger an accumulation of p27 Kip1 protein content, as shown in Fig. 3B .
DHA stabilizes and inhibits the degradation of p27
Kip1 protein
There are several mechanisms of p27 Kip1 degradation; however, the best characterized is the ubiquitin-dependent degradation by proteasome (18, 19) . Hence, we used a chemical inhibitor of the proteasome, MG132, to inhibit p27
Kip1 degradation. Figure 4A shows that treatment of FM3A cells with MG132 induced p27
Kip1 accumulation. When the cells were treated with MG132 and MEK inhibitor, U0126, or DHA, no further increase in p27 Kip1 was observed.
To assess directly the effects of DHA on p27
Kip1 degradation, we first investigated the stability of p27 Kip1 in the presence of the protein synthesis inhibitor cycloheximide. We determined the half-life of the p27
Kip1 protein. Figure 4B shows that p27 Kip1 is completely degraded in 4 h in the exponentially growing cells. Furthermore, we performed another experiment in which the control cells, after 1 h of seeding, were added with cycloheximide alone or with U0126 or DHA. After 2 h of further culture, cell lysates were prepared in order to determine the effects of these agents on p27
Kip1 degradation. The Western blot detection of p27
Kip1 levels showed that DHA and MEK inhibition by U0126 impaired the degradation of p27
Kip1 protein levels in FM3A cells (Fig. 4C ).
DHA inhibits expression of CDK2 and cyclin E
The ubiquitin-dependent proteasome degradation of p27 Kip1 occurs after phosphorylation by CDK2 on Thr-187. Cyclin E is an activator of CDK, and its accumulation is known to activate CDK2 in the late-G 1 phase of the cell cycle. We, therefore, detected phosphorylated CDK2 and assayed its kinase activity. CDK2 protein was increased by serum stimulation in FM3A cells, and DHA diminished the phosphorylated form (33 kDa) of CDK2 (Fig. 5A) . Furthermore, DHA diminished the serum-induced CDK2 kinase activity in FM3A cells (Fig. 5B) . DHA failed to influence the expression of cyclin D1 in serum-stimulated cells (Fig. 5A) . We failed to detect other isoforms of cyclin D in these cells (results not shown). The phosphorylation of cyclin E was enhanced during stimulation of FM3A cells, whereas DHA curtailed the degree of the same (Fig. 5A) .
DHA induces hypophosphorylation of pRb
Because phosphorylation of pRb is necessary for the progression through the cell cycle, we assessed the timecourse of phosphorylation of pRb. In serum-starved cells, pRb appears in the hypophosphorylated form; however, after 6 h of stimulation, another band of lower mobility appears, which corresponds to the hyperphosphorylated form and persists for 24 h (results not shown). Figure 6 shows that DHA inhibits hyperphosphorylation of pRb in FM3A cells.
DISCUSSION
The present study was conducted to elucidate the effects of DHA on FM3A mouse mammary cancer cell prolifer- ation. FM3A cells represent a good model for studying cell growth, because they do not die due to apoptosis (30) . In the present study, we employed DHA, because this is the terminal molecule of the n-3 PUFA family. Externally added fatty acids are readily complexed with free albumin. Hence, fatty acids, after their internalization, are metabolized, and their cellular effects are different from those in free fatty acid forms. Because we wanted to assess the effects of free DHA, we minimized the probabilities of its complexation with a high quantity of albumin by employing fetal calf serum at low concentrations. This type of strategy has also been adopted by other investigators (15) . We observed that DHA inhibited FM3A cell growth at a relatively physiological concentration, i.e., 10 mM. On the other hand, AA, a PUFA of the n-6 family, did not exert growth-inhibitory effects at this concentration in FM3A cells. Our observations on the inhibition of cell proliferation are in agreement with the results of several other authors (6) (7) (8) 31 ) who have shown that this fatty acid exerts anti-proliferative effects on cancer cells.
To determine whether DHA-induced inhibition of cell growth is due to its specific action on the cell cycle, we assessed cell cycle progression. We observed that there were fewer cells in the S phase of the cell cycle in DHAtreated cells than in the serum-stimulated cells. Similarly, the number of cells in the G0/G 1 phase of the cell cycle was higher in DHA-treated cells than in the serum-stimulated cells. Our observations on the specific effects of DHA on the inhibition of cell cycle progression corroborate the findings of Albino et al. (15) , who have demonstrated that DHA inhibits the growth of human melanoma cells by inhibiting the entry of these cells into the S phase of the cell cycle. Terano et al. (27) have also observed that both DHA and EPA inhibit the proliferation of vascular It has been shown that the proteolysis of p27 Kip1 begins in the late-G 1 phase of the cell cycle (32) . We observed that p27
Kip1 was downregulated in serum-stimulated cells, whereas DHA treatment blocked this phenomenon. Delmas et al. (33) have shown that ERK1/ERK2 phosphorylation induces the degradation of p27
Kip1 levels without influencing protein synthesis in choroidal melanoma cells. Moreover, we have demonstrated that DHA inhibits phosphorylation of ERK1/ERK2 (29, 34) and proliferation of T-lymphocytes (35) and NIH/3T3 cells (36). Fig. 1 for 12 h in the presence or absence of DHA (10 mM), MG132 (10 mM), and U0126 (10 mM). STIM, cells stimulated with 0.2% FCS. B: Cells were serum-starved for 6 h (quiescent cells) and stimulated to grow with 0.2% FCS in the presence of cycloheximide (CHX at 75 mM) for different times (0 to 4 h). Cell lysates were prepared, and immunoblotting was performed as described in Materials and Methods. C: Cells were serum-starved for 6 h (quiescent cells, QUIE) and reseeded in the presence of 0.2% FCS (STIM). After 1 h, cycloheximide (CHX at 75 mM) was added to the medium with or without U0126 or DHA. Cell lysates were prepared, after 2 h of culture, and immunoblotting was performed as described in Materials and Methods. NS 5 nonsignificant. Kip1 by DHA and these agents involves posttranscriptional mechanisms, although both of the mechanisms, i.e., transcriptional and posttranscriptional, have been reported to exist in other cells, depending on cell type (33, 38) . However, posttranscriptional control, viz. proteolytic degradation, of p27
Kip1 is a common phenomenon (except in some particular cell systems) that takes place through a ubiquitin-dependent proteasome pathway (38) . To determine whether DHA blocks the proteasome degradation of the p27
Kip1 protein, we employed MG132, the proteasome inhibitor. Indeed, MG132 inhibited the degradation of p27
Kip1 in FM3A cells. The DHA and MEK inhibitor U0126 did not evoke an additive accumulation of p27
Kip1 levels in the presence of MG132. These observations suggest that DHA-induced upregulation of p27
Kip1 is the consequence of the blockade of p27
Kip1 degradation by this fatty acid and that the proteasome pathway may be implicated in this phenomenon. Although there are also other pathways of p27
Kip1 degradation, such as calpain-mediated proteolysis (39), we can rule out, at least, the implication of a caspase-dependent pathway, inasmuch as we did not observe, during immunoblotting, the appearance of 22 kDa and 14 kDa bands (40) , the caspase-dependent cleavage products of p27 Kip1 (results not shown). Furthermore, by employing cycloheximide, we evaluated the half-life of p27
Kip1 degradation and observed that after 4 h, p27
Kip1 was totally degraded. Hence, the DHA and MEK inhibitor U0126 stabilized p27
Kip1 protein and blocked its further degradation in the presence of cycloheximide. Because the ERK1/ERK2 cascade is required for p27
Kip1 downregulation and late-G 1 phase exit (41) , our study does show that DHA inhibits MAPK-dependent degradation of p27
Kip1 in accordance with a recent study (37) showing that MAPK inhibition was found to inhibit the proliferation of six pancreatic cell lines by upregulating p27
Kip1 levels.
P27
Kip1 is a specific inhibitor of CDK2/cyclin E. CDK2, via its association with cyclin E, is involved in the regulation of the G 1 -to-S transition (18, 19) . In our study, DHA did not inhibit cyclin D1 expression, suggesting that the cyclin D/CDK4/6 complex, activated in the early G 1 phase but not in late G 1 phase, is not influenced by DHA (16) . On the other hand, DHA was found to inhibit cyclin E phosphorylation and CDK2 levels. Moreover, DHA inhibited H1 kinase activity of CDK2. In fact, the CDK2/cyclin E complex is known to phosphorylate pRb, because this complex acts as an Rb-kinase (16, 20) . It is well known that pRb is hypophosphorylated in the G0/G 1 phase and hyperphosphorylated in the G 1 -to-S-phase transition. Phosphorylation of pRb results in the dissociation of pRb and the release of a transcription factor (E2F-1) that induces the S-phase entry (16, 20) . In the present study, we observed that DHA inhibited pRb hyperphosphorylation. The inhibition of pRb hyperphosphorylation may be due to DHA-induced reduced activity of CDK2 kinase activity. These observations are in accord with the findings of Albino et al. (15) , who have reported that inhibition of cyclin expression, CDK2 kinase activity, and pRb phosphorylation are responsible for the inhibition of the transition of WI-38 cells from the G 1 to the S phase of the cell cycle.
In conclusion, our findings provide new insights into the mechanism of action of DHA in the regulation of cell proliferation. Our observations demonstrate that DHA, a PUFA of the n-3 family, induced cell cycle arrest in the late-G 1 to S phase of the cell cycle by inhibiting the MAPK activation and proteasome degradation of p27
Kip1 in FM3A cells. DHA also inhibits CDK2 kinase activity and hyperphosphorylation of pRb in these cells.
